These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26932771)

  • 1. An optimal stratified Simon two-stage design.
    Parashar D; Bowden J; Starr C; Wernisch L; Mander A
    Pharm Stat; 2016 Jul; 15(4):333-40. PubMed ID: 26932771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sequential enrichment designs for phase II clinical trials.
    Zang Y; Yuan Y
    Stat Med; 2017 Jan; 36(1):54-66. PubMed ID: 27640874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials.
    Cabarrou B; Leconte E; Sfumato P; Boher JM; Filleron T
    BMC Med Res Methodol; 2022 Oct; 22(1):278. PubMed ID: 36289451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies.
    Jones CL; Holmgren E
    Contemp Clin Trials; 2007 Sep; 28(5):654-61. PubMed ID: 17412647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
    Mistry P; Dunn JA; Marshall A
    BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package.
    Cabarrou B; Sfumato P; Leconte E; Boher JM; Filleron T
    Comput Biol Med; 2018 Sep; 100():239-246. PubMed ID: 30055524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point estimation and p-values in phase II adaptive two-stage designs with a binary endpoint.
    Kunzmann K; Kieser M
    Stat Med; 2017 Mar; 36(6):971-984. PubMed ID: 28028823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.
    Englert S; Kieser M
    Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified varying-stage adaptive phase II/III clinical trial design.
    Dong G; Vandemeulebroecke M
    Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal flexible designs in phase II clinical trials.
    Chen TT; Ng TH
    Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling.
    Gajewski BJ; Berry SM; Barsan WG; Silbergleit R; Meurer WJ; Martin R; Rockswold GL
    Pharm Stat; 2016 Sep; 15(5):396-404. PubMed ID: 27306921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.